RxDoctor Payments Data

Tamara Yeager

Family · Martinsburg, WVNPI 1972087955

Payments from drug & device makers

$510in general payments, 2019–2025

Across 21 payments — averaging $24.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$184
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$115
  • Medtronic$62
  • Davol Inc.$62
  • Novartis$39
  • Irhythm Technologies, Inc.$29
  • plus $19 from 1 others

What the payments were for

  • Food & beverage$49697%
  • Education$143%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$510 in reported general payments places this provider in the 55th percentile of 1,507 family providers in West Virginia.

See all family providers in West Virginia

Medicare billing

Part B allowed, 2024
$27,460
Medicare patients
264
Services billed
329

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban323$382,223
EntrestoSacubitril/Valsartan133$147,926
XareltoRivaroxaban100$119,488
FarxigaDapagliflozin Propanediol52$70,486
Repatha SureclickEvolocumab52$43,013
BrilintaTicagrelor43$40,986
JardianceEmpagliflozin21$20,173
Metoprolol Succinate351$4,521
Atorvastatin Calcium412$3,944
Ranolazine ErRanolazine27$3,031
Rosuvastatin Calcium212$3,000
Carvedilol328$2,448
ClopidogrelClopidogrel Bisulfate183$1,725
Ezetimibe88$1,633
Amiodarone Hcl69$1,472

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$39$147,926133 claims
Johnson & JohnsonXarelto$19$119,488100 claims
AstraZenecaFarxiga, Brilinta$184$111,47295 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,507 family providers in West Virginia.

Other family in Martinsburg

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →